Invitae Corporation today announced that
it plans to defend its right to provide naturally occurring genetic
information and services to physicians for their cancer patients through
…
Invitae Corporation today announced that
it plans to defend its right to provide naturally occurring genetic
information and services to physicians for their cancer patients through
its genetic testing services. Invitae has been named a defendant in a
lawsuit filed by Myriad Genetics MYGN regarding Invitae's BRCA and
MUTYH genetic tests. Invitae disagrees with the allegations of the
lawsuit and plans to vigorously defend itself against the lawsuit, which
it believes has no merit.
Earlier this year, the Supreme Court ruled that naturally occurring DNA
and the information it encodes cannot be patented (Assn'n for Molecular
Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 [2013]) and thus
ushered in a
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in